Patents by Inventor Warren Hurlburt

Warren Hurlburt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
    Patent number: 8492328
    Abstract: IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: July 23, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fei Huang, Xia Han, Rameh Hafezi, Jiwen Chen, Douglas Michael Robinson, Gayle M. Wittenberg, Ashok Ramesh Dongre, Joan M. Carboni, Ricardo M. Attar, Warren Hurlburt, Marco M. Gottardis
  • BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO INSULIN GROWTH FACTOR-1 RECEPTOR MODULATORS
    Publication number: 20100184125
    Abstract: IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
    Type: Application
    Filed: May 15, 2008
    Publication date: July 22, 2010
    Inventors: Fei Huang, Xia Han, Rameh Hafezi, Jiwen Chen, Douglas Michael Robinson, Gayle M. Wittenberg, Ashok Ramesh Dongre, Joan M. Carboni, Ricardo M. Attar, Warren Hurlburt, Marco M. Gottardis